Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney failure. It is a genetic condition which causes cysts to develop in the kidneys and can eventually lead to kidney failure.
Currently, there is only one approved treatment for ADPKD. While this treatment can be effective at slowing the disease down, it can cause serious side effects relating to the liver.
The study drug, RT‑312 has been designed to avoid these harmful side effects in the liver, providing a potentially safer medication to those living with ADPKD.
The start date for this study is flexible. If you pass the initial screening, the study coordinator will work with you to schedule your exact dates.
Please note that you can only be admitted between Sunday and Thursday.
Requirements
- Male or Female
- Healthy
- 18 - 45 years old
- BMI 18 - 32 kg/m2
- Not taking any medications
- Non-smoker or Occasional smoker
Study visits
6 nights, 2 clinic visits
Remuneration
$4,100 - $4,350